Tarsus Pharmaceuticals, Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
TARS$73.83+4.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
(In thousands, except share data)
| Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · TotalStockholders’Equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||||
| Balance as of December 31, 2025 | 42,553,931 | $6 | $769,667 | $381 | $(426,628) | $343,426 | |||||
| Net loss | — | — | — | — | (6,967) | (6,967) | |||||
| Recognition of stock-based compensation expense | — | — | 11,967 | — | — | 11,967 | |||||
| Exercise of vested stock options | 45,394 | — | 1,204 | — | — | 1,204 | |||||
| Issuance of common stock upon the vesting of restricted stock units | 421,987 | — | — | — | — | — | |||||
| Other comprehensive income (loss) | — | — | (679) | — | (679) | ||||||
| Balance as of March 31, 2026 | 43,021,312 | $6 | $782,838 | $(298) | $(433,595) | $348,951 | |||||
| Net loss | — | — | — | — | (18,551) | (18,551) | |||||
| Recognition of stock-based compensation expense | — | — | 13,289 | — | — | 13,289 | |||||
| Exercise of vested stock options | 91,548 | — | 1,864 | — | — | 1,864 | |||||
| Issuance of common stock upon the vesting of restricted stock units | 131,601 | — | — | — | — | — | |||||
| Shares issued in connection with the employee stock purchase plan | 26,886 | — | 1,438 | — | — | 1,438 | |||||
| Other comprehensive income (loss) | — | — | — | (259) | — | (259) | |||||
| Balance as of June 30, 2026 | 43,271,347 | $6 | $799,429 | $(557) | $(452,146) | $346,732 | |||||
| Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of December 31, 2024 | 38,349,826 | $6 | $584,559 | $179 | $(360,210) | $224,534 |
| Net loss | — | — | — | — | (25,120) | (25,120) |
| Recognition of stock-based compensation expense | — | — | 6,930 | — | — | 6,930 |
| Issuance of common stock, net of issuance costs of $9.0 million | 3,230,336 | — | 134,771 | — | — | 134,771 |
| Exercise of vested stock options | 78,436 | — | 1,437 | — | — | 1,437 |
| Issuance of common stock upon the vesting of restricted stock units | 336,939 | — | — | — | — | — |
| Other comprehensive income (loss) | — | — | — | (94) | — | (94) |
| Balance as of March 31, 2025 | 41,995,537 | $6 | $727,697 | $85 | $(385,330) | $342,458 |
| Net loss | — | — | — | — | (20,340) | (20,340) |
| Recognition of stock-based compensation expense | — | — | 8,234 | — | — | 8,234 |
| Exercise of vested stock options | 56,795 | — | 1,205 | — | — | 1,205 |
| Issuance of common stock upon the vesting of restricted stock units | 126,639 | — | — | — | — | — |
| Shares issued in connection with the employee stock purchase plan | 32,001 | — | 1,101 | — | — | 1,101 |
| Other comprehensive income (loss) | — | — | — | (46) | — | (46) |
| Balance as of June 30, 2025 | 42,210,972 | $6 | $738,237 | $39 | $(405,670) | $332,612 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.